Protagonist Therapeutics, Inc. announced that Pivotal Phase 3 VERIFY study of rusfertide in polycythemia vera expected to initiate in first quarter of 2022. Topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis expected in second quarter of 2022. Dosing has begun in a 240-patient Phase 2b clinical trial of PN-235 in moderate-to-severe plaque psoriasis, sponsored by Janssen.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.09 USD | +2.15% | +3.74% | +13.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.78% | 1.53B | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Protagonist Therapeutics, Inc. Announces Pivotal Phase 3 VERIFY Study of Rusfertide in Polycythemia Vera Expected to Initiate in First Quarter of 2022